RP-3 by Replimune for Head And Neck Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Head And Neck Cancer.

Pharmalittle: We’re reading about Medicare price negotiations, slowing layoffs, and more

Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are racing madly about the Pharmalot grounds

February 1, 2024

New portable biosensor could revolutionize heart failure screening at home

Heart failure is a leading cause of death worldwide and is especially fatal for people who don’t have access to medical facilities. So, a team

August 19, 2024

Pediatric RSV infections surged 2017-23, straining U.S. hospitals

A recent study found a significant post-pandemic surge in pediatric RSV infections, with increased hospitalizations and respiratory support needs, especially among older children.

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.